Type 2 Diabetes Clinical Trial
— ARRAOfficial title:
Sequences of Aerobic and Resistance Exercise in Training and Their Effects on Cardio-metabolic Functions Among Type 2 Diabetes Patients - a Randomized Study
Aerobic exercise and resistance exercise are two types of exercise commonly used in physical conditioning. Compared to aerobic exercise, a combination of aerobic and resistance exercise has been linked to a greater reduction in hemoglobin A1c (HbA1c) among patients with type 2 diabetes (T2D). However, it is not clear that in a concurrent aerobic-resistance training session, whether the orders of the two types of exercise could act differently in glucose metabolism. This pilot randomized trial aims to investigate the effect of the sequence of exercise modalities (aerobic-resistance vs resistance-aerobic in a training session) on glycemic control among T2D patients following an 8-wk intervention period. The trial also aims to compare the effects of the two different sequences in blood pressure, sleep quality, and lower limb muscle strength among the T2D population.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | March 1, 2024 |
Est. primary completion date | March 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 72 Years |
Eligibility | Inclusion Criteria: - Age 40-72 years; - Type 2 diabetes diagnosed as: random blood glucose =11.1mmol/L (200mg/dL) or fasting blood glucose =7.0mmol/L (126mg/L) or oral glucose tolerance test (2h) =11.1mmol/L (200mg/dL) or glycated hemoglobin (HbA1c) = 6.5%; - The course of type 2 diabetes lasted for one year or longer; - Willing to participate and sign the informed consent form voluntarily Exclusion Criteria: - Type 1 diabetes; - Fasting blood glucose (FBG)>16.7mmol/L; - Severe complications of diabetes such as acute infection, diabetic ketoacidosis, and plantar lesions; - Severe kidney disease, cardiovascular and cerebrovascular diseases as identified by a specialist; - Musculoskeletal, neurological, psychiatric or other disorders which limit the ability to exercise as identified by a specialist; - Doing physical exercise regularly (= 3 times per week, at least 1 hour per session of moderate to vigorous activities); - Systolic blood pressure =160 mmHg and/or diastolic blood pressure =100 mmHg at rest; - Abnormal electrocardiogram (rest and exercise); - Other comorbidities or medications irrelevant to diabetes treatment that may influence glycemia during the past 6 months |
Country | Name | City | State |
---|---|---|---|
China | Maigaoqiao Community Health Service Center | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Zhejiang University | Karolinska Institutet, Nanjing Sport Institute |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fasting glucose at baseline | blood glucose level following overnight (12-h) fasting | At baseline, within 7 days before the intervention starts | |
Primary | Fasting glucose at follow-up | blood glucose level following overnight (12-h) fasting | At week 9, within 7 days after the completion of the 8-week intervention | |
Primary | Hemoglobin A1c (HbA1c) at baseline | HbA1c level in blood | At baseline, within 7 days before the intervention starts | |
Primary | Hemoglobin A1c (HbA1c) at follow-up | HbA1c level in blood | At week 9, within 7 days after the completion of the 8-week intervention | |
Primary | Fasting insulin at baseline | blood insulin level following overnight (12-h) fasting | At baseline, within 7 days before the intervention starts | |
Primary | Fasting insulin at follow-up | blood insulin level following overnight (12-h) fasting | At week 9, within 7 days after the completion of the 8-week intervention | |
Primary | Continuous glucose monitoring at baseline | 14-day continuous glucose monitoring | At baseline, within 14 days before the intervention starts, measurement lasts for 14 days | |
Primary | Continuous glucose monitoring at follow-up | 14-day continuous glucose monitoring | At week 9-10, within 14 days after the completion of the 8-week intervention | |
Secondary | Total nocturnal sleep duration and at baseline | total sleep duration (in minutes) and total awakening duration after sleep onset (in minutes) assessed by wrist actigraphy (GT3x, Actigraph LLC, Pensacola, FL, USA) | At baseline, within 14 days before the intervention (observation) starts, measurement lasts for at least 7 days | |
Secondary | Total nocturnal sleep duration and total awakening duration at follow-up | total sleep duration (in minutes) and total awakening duration after sleep onset (in minutes) assessed by wrist actigraphy (GT3x, Actigraph LLC, Pensacola, FL, USA) | At week 9-10, within 14 days after the completion of the 8-week intervention, measurement lasts for at least 7 days | |
Secondary | Insomnia Severity Index (ISI) at baseline | Insomnia Severity Index (0-28), higher score means more severe insomnia | At baseline, within 7 days before the intervention starts | |
Secondary | Insomnia Severity Index (ISI) at follow-up | Insomnia Severity Index (0-28), higher score means more severe insomnia | At week 9, within 7 days after the completion of the 8-week intervention | |
Secondary | Epworth Sleepiness Scale (ESS) at baseline | Epworth Sleepiness Scale (1-24), higher score means more sleepiness | At baseline, within 7 days before the intervention starts | |
Secondary | Epworth Sleepiness Scale (ESS) at follow-up | Epworth Sleepiness Scale (1-24), higher score means more sleepiness | At week 9, within 7 days after the completion of the 8-week intervention | |
Secondary | Berlin Questionnaire at baseline | High Risk: if there are 2 or more categories where the score is positive. Low Risk: if there is only 1 or no categories where the score is positive. | At baseline, within 7 days before the intervention starts | |
Secondary | Berlin Questionnaire at at follow-up | High Risk: if there are 2 or more categories where the score is positive. Low Risk: if there is only 1 or no categories where the score is positive. | At week 9, within 7 days after the completion of the 8-week intervention | |
Secondary | Diagnostic Interview for Sleep Patterns and Disorders (DISP) at baseline | Sleep patterns and disorders | At baseline, within 7 days before the intervention starts | |
Secondary | Diagnostic Interview for Sleep Patterns and Disorders (DISP) at follow-up | Sleep patterns and disorders | At week 9, within 7 days after the completion of the 8-week intervention (observation) | |
Secondary | Height at baseline | height in meters | At baseline, within 7 days before the intervention starts | |
Secondary | Height at follow-up | height in meters | At week 9, within 7 days after the completion of the 8-week intervention | |
Secondary | Weight at baseline | weight in kilograms | At baseline, within 7 days before the intervention starts | |
Secondary | Weight at follow-up | weight in kilograms | At week 9, within 7 days after the completion of the 8-week intervention (observation) | |
Secondary | K-Force measurement of static and dynamic balance at baseline | measurement of static and dynamic balance in a wide range of movements | At baseline, within 7 days before the intervention starts | |
Secondary | K-Force measurement of static and dynamic balance at follow-up | measurement of static and dynamic balance in a wide range of movements | At week 9, within 7 days after the completion of the 8-week intervention | |
Secondary | Musculoskeletal ultrasound at baseline | Quadriceps cross-sectional area and thickness | At baseline, within 7 days before the intervention starts | |
Secondary | Musculoskeletal ultrasound at follow-up | Quadriceps cross-sectional area and thickness | At week 9, within 7 days after the completion of the 8-week intervention | |
Secondary | International Physical Activity Questionnaire - Short Form at baseline | International Physical Activity Questionnaire (IPAQ) - Short Form for assessing level of physical activity. Level of physical activity are calculated into metabolic equivalent minutes per week (MET mins/wk) according to the answers of the questionnaire. Higher MET mins/wk refers to higher level of physical activity. | At baseline, within 7 days before the intervention starts | |
Secondary | International Physical Activity Questionnaire - Short Form at follow-up | International Physical Activity Questionnaire (IPAQ) - Short Form for assessing level of physical activity. Level of physical activity are calculated into metabolic equivalent minutes per week (MET mins/wk) according to the answers of the questionnaire. Higher MET mins/wk refers to higher level of physical activity. | At week 9, within 7 days after the completion of the 8-week intervention | |
Secondary | Food Frequency Questionnaire at baseline | Food frequency within 7 days | At baseline, within 7 days before the intervention starts | |
Secondary | Food Frequency Questionnaire at follow-up | Food frequency within 7 days | At week 9, within 7 days after the completion of the 8-week intervention | |
Secondary | Ambulatory Blood Pressure at baseline | Repeated measurement of blood pressure every 30 mins over a 24-h period, device attached on participant's waist with a cuff attached to the left upper arm | At baseline, within 7 days before the intervention starts, any day within the measurement period of continuous glucose monitoring and actigraphy | |
Secondary | Ambulatory Blood Pressure at follow-up | Repeated measurement of blood pressure every 30 mins over a 24-h period, device attached on participant's waist with a cuff attached to the left upper arm | At week 9, within 7 days before the intervention starts, any day within the measurement period of continuous glucose monitoring and actigraphy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |